Prime Capital Investment Advisors LLC Has $2.73 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Prime Capital Investment Advisors LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,739 shares of the biopharmaceutical company's stock after selling 9,233 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in Gilead Sciences were worth $2,727,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Gilead Sciences by 2.6% in the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company's stock valued at $8,404,161,000 after purchasing an additional 2,910,147 shares during the last quarter. Capital World Investors lifted its position in shares of Gilead Sciences by 1.4% during the first quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company's stock worth $6,189,435,000 after purchasing an additional 1,133,281 shares during the last quarter. Capital Research Global Investors grew its stake in Gilead Sciences by 2.7% in the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company's stock worth $4,486,296,000 after purchasing an additional 1,589,240 shares in the last quarter. Wellington Management Group LLP raised its stake in Gilead Sciences by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company's stock valued at $1,509,227,000 after buying an additional 2,350,550 shares in the last quarter. Finally, Parnassus Investments LLC raised its position in shares of Gilead Sciences by 0.3% during the 4th quarter. Parnassus Investments LLC now owns 11,952,057 shares of the biopharmaceutical company's stock valued at $968,236,000 after acquiring an additional 36,686 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GILD. BMO Capital Markets increased their price objective on Gilead Sciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. Truist Financial upped their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a "hold" rating in a research note on Thursday, August 15th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Evercore ISI raised Gilead Sciences to a "strong-buy" rating in a report on Friday, August 9th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $95.00 target price on shares of Gilead Sciences in a report on Wednesday, September 11th. Twelve investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $82.06.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. In the last three months, insiders sold 36,847 shares of company stock valued at $3,002,940. Company insiders own 0.16% of the company's stock.

Gilead Sciences Stock Performance

GILD traded down $0.11 on Tuesday, hitting $83.05. The company had a trading volume of 7,077,490 shares, compared to its average volume of 7,171,680. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The company's fifty day moving average price is $75.79 and its 200 day moving average price is $70.92. The stock has a market cap of $103.47 billion, a price-to-earnings ratio of 230.81, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Equities analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.71%. The ex-dividend date is Friday, September 13th. Gilead Sciences's dividend payout ratio is 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.